Barrow Hanley Mewhinney & Strauss LLC Cuts Stake in Humana Inc. (NYSE:HUM)

Barrow Hanley Mewhinney & Strauss LLC cut its holdings in Humana Inc. (NYSE:HUM) by 23.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 680,733 shares of the insurance provider’s stock after selling 203,325 shares during the period. Barrow Hanley Mewhinney & Strauss LLC owned 0.56% of Humana worth $254,356,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in HUM. Intech Investment Management LLC boosted its position in shares of Humana by 46.2% during the fourth quarter. Intech Investment Management LLC now owns 42,287 shares of the insurance provider’s stock worth $19,359,000 after acquiring an additional 13,356 shares during the last quarter. AdvisorShares Investments LLC purchased a new position in shares of Humana during the fourth quarter valued at about $421,000. Sei Investments Co. increased its holdings in shares of Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock worth $21,462,000 after purchasing an additional 264 shares during the last quarter. Cetera Advisors LLC increased its holdings in shares of Humana by 472.1% in the first quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock worth $3,501,000 after purchasing an additional 8,333 shares during the last quarter. Finally, Cetera Investment Advisers lifted its position in shares of Humana by 249.0% in the first quarter. Cetera Investment Advisers now owns 20,945 shares of the insurance provider’s stock worth $7,262,000 after buying an additional 14,944 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Down 0.5 %

Shares of HUM opened at $310.41 on Friday. The firm has a fifty day moving average price of $357.71 and a 200-day moving average price of $345.61. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $37.40 billion, a P/E ratio of 19.33, a P/E/G ratio of 2.56 and a beta of 0.50. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $530.54.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same period in the prior year, the firm earned $8.94 EPS. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities research analysts expect that Humana Inc. will post 16 earnings per share for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date of this dividend is Monday, September 30th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Royal Bank of Canada lifted their price objective on Humana from $385.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, September 5th. Piper Sandler assumed coverage on shares of Humana in a research report on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target on the stock. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Truist Financial boosted their target price on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. increased their price target on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $398.70.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.